Prodeon Medical Highlights the Urocross Expander System Clinical Results at the American Urological Association (AUA) 2026 Annual Meeting

Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s): A Pivotal, Randomized, Sham-Controlled Trial of the Urocross Expander System for Treatment of LUTS due to BPH – 30 Month Safety ...
Mena FN

Prodeon Medical Receives FDA 510(K) Clearance For The Urocross® Expander System, A Novel Non-Permanent Retrievable Implant For Treating Urinary Symptoms Associated With Benign ...

(MENAFN- GlobeNewsWire - Nasdaq) The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no ...
The Hamilton Spectator

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign ...

SUNNYVALE, Calif., March 16, 2026 (GLOBE NEWSWIRE) — Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced ...